Notice to 340B Covered Entities Regarding Calcium Acetate (Generic) Capsules

September 25, 2019

Fresenius Medical Care North America (“FMCNA”) has a limited supply of calcium acetate (generic) capsules (NDC 49230-0644-41) (the “Product”) that it will sell, beginning October 2, 2019 on a first come, first served basis. This notice provides information for eligible 340B covered entities about how to acquire the Product at the 340B price.

Because of the limited, one-time supply of the Product, FMCNA has implemented a limited distribution system (the “System”). The System will make available 63,500 units of the Product for purchase on a first-come, first-served basis, to any customer, including any 340B covered entities, that place an order for the Product through an approved wholesaler or distributor.

FMCNA’s wholesalers and distributors will be implementing the System. To purchase the Product, 340B covered entities may purchase the Product through any of these wholesalers and distributors. The approved wholesalers and distributors are:

AmerisourceBergen Corporation,

Cardinal Health Inc., and

McKesson Corporation.

FMCNA will instruct its wholesalers and distributors to take and pass through all Product orders without regard to the 340B participation status of any customer.

The System will remain in place until all available Product is depleted. We are implementing this limited distribution system in order to best ensure that all patients of all providers have fair and equitable access. FMCNA appreciates your cooperation during this period.

If you have any questions, please contact Pasquale “Pat” Penta, Senior Director, Managed Markets at [Pasquale.Penta@fmc-na.com or 781-999-3184].